ArticleNature protocols2018
Preparation of chiral-at-metal catalysts and their use in asymmetric photoredox chemistry.
Article in Nature protocols, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 101 citations in OpenAlex.
- Imidazol-2-ylidene-Based NCCN Ligands for Chiral-at-Iron Catalysis.Organometallics · 2026Article
- A metal-DNA biohybrid as enantioselective artificial photoDNAzyme.Nature communications · 2026Article
- Bright Circularly Polarized Electrochemiluminescence from Heterobinuclear IrAngewandte Chemie (International ed. in English) · 2026Article
- Privileged Chiral Photocatalysts.Angewandte Chemie (International ed. in English) · 2025Review
- Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies.Journal of translational medicine · 2025Review
- Cobalt catalyst with exclusive metal-centered chirality for asymmetric photocatalysis.Nature communications · 2025Article
- Enantioselective photocatalytic synthesis of bicyclo[2.1.1]hexanes as ortho-disubstituted benzene bioisosteres with improved biological activity.Nature chemistry · 2025Article
- Chemistry of 2-(2'-Aminophenyl)benzothiazole Derivatives: Syntheses, Photophysical Properties and Applications.Molecules (Basel, Switzerland) · 2025Review
- Chiral-at-metal catalysts: history, terminology, design, synthesis, and applications.Chemical Society reviews · 2025Review
- Ringing the Changes: Effects of Heterocyclic Ring Size on Stereoselectivity in [(ηMolecules (Basel, Switzerland) · 2024Article
- AChemical science · 2024Article
- Highly Enantioselective Lewis Acid Catalyzed Conjugate Addition of Imidazo[1,2-The Journal of organic chemistry · 2024Article
- Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells.Journal of medicinal chemistry · 2023Article
- Synthesis of the Brivaracetam Employing Asymmetric Photocatalysis and Continuous Flow Conditions.ACS omega · 2023Article
- Detection and analysis of chiral molecules as disease biomarkers.Nature reviews. Chemistry · 2023Review
- Looking for chiral recognition in photoinduced bimolecular electron transfer using ultrafast spectroscopy.Physical chemistry chemical physics : PCCP · 2023Article
- Metal Stereogenicity in Asymmetric Transition Metal Catalysis.Chemical reviews · 2023Review
- Symmetry-breaking host-guest assembly in a hydrogen-bonded supramolecular system.Nature communications · 2023Article
- Improving the Configurational Stability of Chiral-at-Iron Catalysts Containing TwoOrganometallics · 2022Article
- Ru(II)-Catalyzed Hydroarylation of in situ Generated 3,3,3-Trifluoro-1-propyne by C-H Bond Activation: A Facile and Practical Access to β-Trifluoromethylstyrenes.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asymmetric catalysis is a powerful approach for the synthesis of optically active compounds, and visible light constitutes an abundant source of energy to enable chemical transformations, which are often triggered by photoinduced electron transfer (photoredox chemistry). Recently, bis-cyclometalated iridium(III) and rhodium(III) complexes were introduced as a novel class of catalysts for combining asymmetric catalysis with visible-light-induced photoredox chemistry. These catalysts are attractive because of their unusual feature of chirality originating exclusively from a stereogenic metal center, which offers the prospect of an especially effective asymmetric induction upon direct coordination of the substrate to the metal center. As these chiral catalysts contain only achiral ligands, special strategies are required for their synthesis. In this protocol, we describe strategies for preparing two types of chiral-at-metal catalysts, namely the Λ- and Δ-enantiomers (left- and right-handed propellers, respectively) of the iridium complex IrS and the rhodium complex RhS. Both contain two cyclometalating 5-tert-butyl-2-phenylbenzothiazoles in addition to two acetonitrile ligands and a hexafluorophosphate counterion. The two cyclometalated ligands set the propeller-shaped chiral geometry, but the acetonitriles are labile and can be replaced by substrate molecules. The synthesis protocol consists of three stages: first, preparation of the ligand 5-tert-butyl-2-phenylbenzothiazole; second, preparation of salicylthiazoline (used for iridium) and salicyloxazoline (used for rhodium) chiral auxiliaries; and third, the auxiliary-mediated synthesis of the individual enantiopure Λ- and Δ-configured catalysts. This class of stereogenic-only-at-metal complexes is of substantial value in the field of asymmetric catalysis, offering stereocontrolled radical reactions based on visible-light-activated photoredox chemistry. Representative examples of visible-light-induced asymmetric catalysis are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.